Ipralin Warnings

Paradoxical Bronchospasm: Ipralin inhaler can produce paradoxical bronchospasm that can be life-threatening. If it occurs, Ipralin should be discontinued immediately and an alternative therapy may be instituted.
Cardiovascular Effect: The salbutamol sulphate contained in Ipralin HFA inhaler, like other β-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure and/or symptoms. Although such effects are uncommon after administration of Ipralin HFA inhaler at recommended doses, if they occur, discontinuation of Ipralin may be indicated. In addition, β-adrenergic agents have been reported to produce electrocardiogram (ECG) changes eg, flattening of the T-wave, prolongation of the QTc interval and ST segment depression. Therefore, Ipralin HFA inhaler should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias and hypertension.
Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
Immediate Hypersensitivity Reactions: Immediate hypersensitivity reactions may occur after administration of ipratropium bromide or salbutamol sulphate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis and oropharyngeal edema.